| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
173,744,000 |
| Market
Cap: |
1.41(B) |
| Last
Volume: |
148,509 |
Avg
Vol: |
0 |
| 52
Week Range: |
$7.6 - $15.45 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 8.3 |
| Insider 6 Months : 8.3 |
| Insider 3/6 Months : 16.7 |
|
| Guru Rank Number : 607 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focusing on developing the treatment of GI diseases. LINZESS® (linaclotide), Co.'s commercial product, is a product in a class of GI medicines called guanylate cyclase type C agonists and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is available to adult men and women suffering from IBS-C or CIC in the U.S. and Mexico and to adult men and women suffering from IBS-C in Japan and China. Co. has partnerships with pharmaceutical companies to support the development and commercialization of linaclotide.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
17,604 |
17,604 |
53,676 |
53,676 |
| Total Buy Value |
$160,420 |
$160,420 |
$460,539 |
$460,539 |
| Total People Bought |
2 |
2 |
2 |
2 |
| Total Buy Transactions |
2 |
2 |
3 |
3 |
| Total Shares Sold |
280,916 |
294,129 |
403,559 |
1,047,483 |
| Total Sell Value |
$4,281,159 |
$4,424,082 |
$5,556,813 |
$12,970,668 |
| Total People Sold |
5 |
6 |
6 |
9 |
| Total Sell Transactions |
5 |
7 |
14 |
48 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sarissa Capital Management Lp |
10% Owner |
– – • |
2023-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,438 |
93,423 |
|
- |
|
| Mccourt Thomas A |
Chief Executive Officer |
• • – |
2023-03-08 |
4 |
A |
$0.00 |
$0 |
D/D |
240,595 |
888,193 |
|
- |
|
| Shetzline Michael |
CMO,SVP,Head-Res&Drug |
• – – |
2023-03-08 |
4 |
A |
$0.00 |
$0 |
D/D |
69,869 |
331,455 |
|
- |
|
| John Minardo |
Chief Legal Officer |
• – – |
2023-03-08 |
4 |
A |
$0.00 |
$0 |
D/D |
65,502 |
199,240 |
|
- |
|
| Rickard Jason |
SVP, Chief Operating Officer |
• – – |
2023-03-08 |
4 |
A |
$0.00 |
$0 |
D/D |
43,668 |
376,316 |
|
- |
|
| Davis Andrew |
SVP, Chief Business Officer |
• – – |
2023-03-08 |
4 |
A |
$0.00 |
$0 |
D/D |
74,236 |
225,632 |
|
- |
|
| Emany Sravan Kumar |
SVP, Chief Financial Officer |
• – – |
2023-03-08 |
4 |
A |
$0.00 |
$0 |
D/D |
74,236 |
152,658 |
|
- |
|
| Silver Ronald |
Principal Accounting Officer |
• – – |
2023-03-08 |
4 |
A |
$0.00 |
$0 |
D/D |
35,620 |
134,111 |
|
- |
|
| Mccourt Thomas A |
Chief Executive Officer |
• • – |
2023-03-03 |
4 |
AS |
$11.22 |
$378,742 |
D/D |
(33,756) |
647,598 |
|
-8% |
|
| Shetzline Michael |
CMO,SVP,Head-Res&Drug |
• – – |
2023-02-28 |
4 |
S |
$11.31 |
$111,449 |
D/D |
(9,854) |
261,586 |
|
9% |
|
| Mccourt Thomas A |
Chief Executive Officer |
• • – |
2023-02-28 |
4 |
S |
$11.31 |
$353,177 |
D/D |
(31,227) |
681,354 |
|
9% |
|
| John Minardo |
Chief Legal Officer |
• – – |
2023-02-28 |
4 |
S |
$11.31 |
$38,624 |
D/D |
(3,415) |
133,738 |
|
9% |
|
| Davis Andrew |
SVP, Chief Business Officer |
• – – |
2023-02-28 |
4 |
S |
$11.31 |
$20,607 |
D/D |
(1,822) |
151,396 |
|
9% |
|
| Silver Ronald |
Principal Accounting Officer |
• – – |
2023-02-28 |
4 |
S |
$11.31 |
$34,484 |
D/D |
(3,049) |
98,491 |
|
9% |
|
| Rickard Jason |
SVP, Chief Operating Officer |
• – – |
2023-02-28 |
4 |
S |
$11.31 |
$197,122 |
D/D |
(17,429) |
332,648 |
|
9% |
|
| Shetzline Michael |
CMO,SVP,Head-Res&Drug |
• – – |
2023-02-27 |
4 |
S |
$11.41 |
$108,030 |
D/D |
(9,468) |
271,440 |
|
11% |
|
| Mccourt Thomas A |
Chief Executive Officer |
• • – |
2023-02-27 |
4 |
S |
$11.41 |
$342,346 |
D/D |
(30,004) |
712,581 |
|
11% |
|
| John Minardo |
Chief Legal Officer |
• – – |
2023-02-27 |
4 |
S |
$11.41 |
$37,448 |
D/D |
(3,282) |
137,153 |
|
11% |
|
| Davis Andrew |
SVP, Chief Business Officer |
• – – |
2023-02-27 |
4 |
S |
$11.41 |
$19,979 |
D/D |
(1,751) |
153,218 |
|
11% |
|
| Silver Ronald |
Principal Accounting Officer |
• – – |
2023-02-27 |
4 |
S |
$11.41 |
$33,420 |
D/D |
(2,929) |
101,540 |
|
11% |
|
| Rickard Jason |
SVP, Chief Operating Officer |
• – – |
2023-02-27 |
4 |
S |
$11.41 |
$191,072 |
D/D |
(16,746) |
350,077 |
|
11% |
|
| Mccourt Thomas A |
Chief Executive Officer |
• • – |
2023-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
30,145 |
742,585 |
|
- |
|
| Shetzline Michael |
CMO,SVP,Head-Res&Drug |
• – – |
2023-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
14,663 |
280,908 |
|
- |
|
| Rickard Jason |
SVP, Chief Operating Officer |
• – – |
2023-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
18,087 |
366,823 |
|
- |
|
| Mccourt Thomas A |
Chief Executive Officer |
• • – |
2023-01-05 |
4 |
AS |
$12.07 |
$1,339,311 |
D/D |
(110,962) |
712,440 |
|
-19% |
|
914 Records found
|
|
Page 3 of 37 |
|
|
0.18 (2.17%) 
